ADReCS

Pharmaceutical Information

Drug Name	Hydralazine
Drug ID	BADD_D01081
Description	Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.[A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.[T691] Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779]
Indications and Usage	Hydralazine is indicated alone or adjunct to standard therapy to treat essential hypertension.[L8782] A combination product with isosorbide dinitrate is indicated as an adjunct therapy in the treatment of heart failure.[L8785]
Marketing Status	approved
ATC Code	C02DB02
DrugBank ID	DB01275
KEGG ID	D08044
MeSH ID	D006830
PubChem ID	3637
TTD Drug ID	D0K1XK
NDC Product Code	Not Available
UNII	26NAK24LS8
Synonyms	Hydralazine \| Hydrallazin \| Hydrazinophthalazine \| Apressin \| Nepresol \| Hydralazine mono-Hydrochloride \| Hydralazine mono Hydrochloride \| mono-Hydrochloride, Hydralazine \| Apressoline \| Apresoline \| Hydralazine Hydrochloride \| Hydrochloride, Hydralazine

Chemical Information

Molecular Formula	C8H8N4
CAS Registry Number	86-54-4
SMILES	C1=CC=C2C(=C1)C=NN=C2NN
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Pulmonary alveolar haemorrhage	24.07.01.015; 22.01.02.005	0.002386%		Not Available
Pulmonary haemorrhage	22.12.01.009; 24.07.01.016	0.000579%
Pulmonary oedema	22.01.03.003; 02.05.02.003	0.000170%
Purpura	24.07.06.005; 23.06.01.004; 01.01.04.003	0.000184%
Pyrexia	08.05.02.003	-	-
Rash	23.03.13.001	-	-	Not Available
Rash morbilliform	23.03.13.005	0.000068%		Not Available
Renal failure	20.01.03.005	0.000341%		Not Available
Renal haemorrhage	24.07.07.002; 20.01.02.013; 12.01.05.004	0.000068%
Renal tubular necrosis	20.01.07.003	0.000102%		Not Available
Renal vasculitis	24.12.04.021; 20.01.07.007; 10.02.02.013	0.000750%		Not Available
Respiratory depression	17.02.05.047; 22.02.01.010	0.000068%		Not Available
Respiratory distress	22.02.01.012	0.000170%		Not Available
Respiratory failure	22.02.06.002; 14.01.04.003	0.000729%
Restlessness	19.11.02.002; 17.02.05.021	0.000150%
Retinal vasculitis	10.02.02.021; 06.04.06.011	0.000068%		Not Available
Retroperitoneal fibrosis	20.06.01.006; 10.02.01.026; 07.07.03.003	-	-	Not Available
Sensory loss	17.02.07.007	-	-	Not Available
Sinus tachycardia	02.03.03.010	0.000184%
Splenomegaly	01.09.02.001	-	-	Not Available
Strangury	20.02.02.017	-	-	Not Available
Supraventricular tachycardia	02.03.03.012	0.000170%
Systemic lupus erythematosus	23.03.02.006; 15.06.02.003; 10.04.03.004	0.001343%		Not Available
Systemic lupus erythematosus rash	23.03.13.007; 15.06.02.005; 10.04.03.005	0.000232%		Not Available
Tachycardia	02.03.02.007	0.000239%		Not Available
Thrombocytopenia	01.08.01.002	-	-	Not Available
Tremor	17.01.06.002	-	-
Urinary retention	20.02.02.011	-	-
Urticaria	23.04.02.001; 10.01.06.001	-	-
Vascular purpura	24.07.06.011; 23.06.01.008; 01.01.04.007	-	-	Not Available

The 5th Page First Pre 5 6 7 Next Last Total 7 Pages